PKCα不能预测非小细胞肺癌的预后

Unsuitable Marker for PKCα to Predict Prognosis of Non-small Cell Lung Cancer

目的研究蛋白激酶C-α(PKCα)在非小细胞肺癌(NSCLC)中所代表的临床意义。方法运用免疫组织化学法(IHC)检测51例NSCLC、21例癌旁和11例肺良性病变组织中PKCα的表达,并采用SPSS13.0软件进行相关统计分析。结果PKCα在NSCLC、癌旁和良性肺病变组织中阳性率分别为74.5%(38/51)、42.9%(9/21)和45.5%(5/11),三组间差异存在统计学意义(P=0.019),肿瘤组阳性率要高于癌旁组织(P=0.010)。PKCα蛋白表达与各临床参数间均无明确相关性(P>0.05)。Kanplan-Meier法提示不同表达状态的PKCα生存曲线和复发转移曲线没有差异(P>0.05)。多因素Cox回归分析提示临床分期和复发转移状态为影响生存的因素,相对危险度(RR)分别为2.600和0.211。结论PKCα可能参与了NSCLC的发生发展,尚不能支持PKCα作为判断肿瘤预后和复发转移的指标。

Objective To investigate the clinical significance of PKCα in non-small cell lung cancer （NSCLC）. Methods The expression of PKCα was deteced in 51 cancer tissues, 21 paracancerous tissues and 11 benign lesions by using immunohistochemistry and analyzed by SPSS 13, 0 software. Results The positive expression rate of PKCa was 74. 5 % （38/51）, 42. 9 % （9/21 ） and 45. 5% （5/11） in NSCLC tissues, paracancerous tissues and benign lesions of lung respectively, and there was a statistically significant difference not only among them（P = 0.019） but between NSCLC tissues and paracancerous tissues （P = 0. 010）. It was also found that the expression of PKCα had no significant correlation with all clinical parameters（P〉0. 05） ,PKCα survival curve and PKCa hazard curve of recurrence or metastasis（P〉0. 05）. The multivariate Cox regression model revealed that the clinical stage and status of recurrence or metastasis in tumors might be considered as two independent prognostic factors in patients survival, whose rela- tive risk（RR） value was 2. 600 and 0. 211 respectively. Conclusion PKCα might be related to the origin and progress of NSCLC, but not be deemed as a marker about evaluating prognosis and recurrence or metastasis in tumors.